By day 28, sensitivity declined 86%, wrinkles 31%, and pore visibility improved. Over 56 days, the combined regimen improved skin quality 17%, reduced sensitivity 73%, and supported use after microneedling and intense pulsed light (IPL); satisfaction was 96%, with zero adverse events.
Relevant if you're working with niacinamide, hyaluronic acid, squalane for aging and sensitivity.
If you're targeting aging, this research supports adding niacinamide to your AM/PM routine. Effective concentration range: 70% based on this study. Timeline to expect: 8 weeks based on study duration.
If you're targeting aging, this research supports adding hyaluronic_acid to your AM/PM routine. Effective concentration range: 70% based on this study. Timeline to expect: 8 weeks based on study duration.
Translated from this study's findings, not a personal prescription. Pair with your existing protocol and your practitioner's guidance.
1. Dermatol Ther (Heidelb). 2026 Nov;16(11):5497-5528. doi: 10.1007/s13555-026-01901-z. Epub 2026 Sep 11. Temporally Optimized Antioxidant Serums for Daytime Defense and Nighttime Repair: A Multicenter Clinical Investigation.
1. Dermatol Ther (Heidelb). 2026 Nov;16(11):5497-5528. doi: 10.1007/s13555-026-01901-z. Epub 2026 Sep 11. Temporally Optimized Antioxidant Serums for Daytime Defense and Nighttime Repair: A Multicenter Clinical Investigation. Conway J(1), Blanché C(2), Grivet-Seyve M(3), Jun M(4), Wai HD(5), Lachmann N(6), Berlin I(7), Farberg AS(8)(9)(10). Author information: (1)Reveal Research Institute, 2110 Research Row, Suite 310B, Dallas, TX, 75235, USA. jconway@revealinstitute.com. (2)Galderma R&D, Barcelona, Spain. (3)Galderma R&D, Dallas, TX, USA. (4)Galderma R&D, Baie-D'Urfé, Canada. (5)Galderma R&D, Singapore, Singapore. (6)Galderma R&D, Sensitive Skincare Faculty, Zug, Switzerland. (7)Galderma R&D, Lausanne, Switzerland. (8)Reveal Research Institute, 2110 Research Row, Suite 310B, Dallas, TX, 75235, USA. (9)University of North Texas Health Science Center, Fort Worth, TX, USA. (10)Bare Dermatology, Dallas, TX, USA. INTRODUCTION: Sensitive skin affects up to 70% of the global population, linked to oxidative stress, barrier dysfunction, and disrupted skin biorhythms. The skin's daytime defense and nighttime repair cycles provide rationale for temporally optimized formulations. We evaluated complementary day and night serums incorporating GALLIC-AOX POWER™ technology, triple molecular weight hyaluronic acid, niacinamide (day), and pro-vitamin B5, centella asiatica, and bifida ferment lysate (night). METHODS: Prospective, multicenter preclinical and clinical studies were conducted across China, the USA, and Europe (September 2024-February 2025). A total of 806 adults (aged 18-70 years, all Fitzpatrick phototypes) were enrolled across ~20 independent studies of the day serum, night serum, or both combined. Because several studies assessed more than one product, subject counts overlap and are not additive: 368 (day), 379 (night), and 168 (regimen). Assessments included bioinstrumentation, digital imaging, blinded clinical grading, antioxidant biomarkers, skin renewal, and Sensiscale-10. RESULTS: The day serum provided significant antioxidant protection: after cigarette smoke challenge, malondialdehyde (MDA) and squalene monohydroperoxide (SQOOH) returned toward baseline (~100% and ~90% neutralization); blue light challenge preserved ~40% of catalase activity. A single application produced immediate hydration (+71%) and barrier improvement (-18% transepidermal water loss (TEWL)) sustained 24 h. By day 28, sensitivity declined 86%, wrinkles 31%, and pore visibility improved. The night serum gave comparable hydration (+60%) and barrier benefits (-15% TEWL), with 94% recovery by day 14 and accelerated renewal from day 21. Sensitivity declined 89%, with gains in radiance (+23%), smoothness (+25%), fine lines (-32%), and tone evenness (+21%). Over 56 days, the combined regimen improved skin quality 17%, reduced sensitivity 73%, and supported use after microneedling and intense pulsed light (IPL); satisfaction was 96%, with zero adverse events. CONCLUSIONS: Temporally optimized day and night serums deliver meaningful improvements in sensitivity, barrier function, antioxidant defense, hydration, and aging across diverse populations, supporting circadian alignment as an evidence-based approach to sensitive skin care. © 2026. The Author(s). DOI: 10.1007/s13555-026-01901-z PMID: 42728530 Conflict of interest statement: Declarations. Conflict of Interest: Aaron S. Farberg serves as an advisor for Galderma. Aaron S. Farberg is an Editorial Board member of Dermatology & Therapy and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Jade Conway has nothing to disclose. Céline Blanché, Mathieu Grivet-Seyve, Ma Jun, Haw Diann Wai, Nadège Lachmann, and Irina Berlin are all employees of Galderma. Ethical Approval: The studies were carried out on cosmetic products whose safety had been assured by the Sponsor and on healthy volunteers; therefore, they did not require Ethics Committee approval or Competent Authority authorization. The single exception was the in-use study performed after mild aesthetic procedures, which received CRO Ethics Committee approval (QDCPCH24000579). Written informed consent was obtained from all participants; formal ethics-committee approval was not required for the cosmetic studies on healthy volunteers, with the exception noted above.
Original source →Friedreich's ataxia is a rare, chronic, progressive, neurodegenerative condition affecting multiple organ systems, including neurological, musculoskeletal, cardiac, and endocrine systems, and is marked by low cardiopulmonary fitness. We tested the effect of exercise and NAD+ precursor supplementation with nicotinamide riboside, which have each shown benefits in animal and early clinical studies, on cardiopulmonary fitness in individuals with Friedreich's ataxia. This 12-week, outpatient, phase 2, single-site (Children's Hospital of Philadelphia, Philadelphia, PA, USA), randomised, 2 × 2 factorial clinical trial recruited individuals aged 10-40 years with an ejection fraction of 45% or greater who were able to exercise.
Wounds continue to represent a significant public health challenge globally. In recent years, Astragalus mongholicus Bunge, a traditional Chinese botanical drug utilized for wound treatment, has garnered increasing research attention. However, the therapeutic efficacy and safety of this natural botanical drug on wound healing remain poorly understood.
Recent preclinical studies have shown that nicotinamide adenine dinucleotide (NAD+) plays a critical role in molecular mechanisms of axon degeneration, and reductions in NAD+ levels are associated with axonal degeneration. Nicotinamide riboside (NR) is a safe and widely available pyridine-nucleoside form of vitamin B3 and is an NAD+ precursor. To investigate if oral supplementation of synthetic NR can act as a therapeutic agent to prevent degeneration of small somatic sensory axons innervating the skin or promote regeneration of these same fibers in humans, we utilized a validated experimental model of cutaneous nerve degeneration and regeneration and conducted a placebo-controlled, double-blinded Phase 2 study.
This information is for educational purposes only and is not medical advice. Individual results vary. Consult a qualified dermatologist or healthcare professional for medical concerns. Full disclaimer →